Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Rui Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8669-6373; OpenAlex author ID A5101821791. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 3

  1. Targeted Cepharanthine-Mediated Dual-Pathway Inhibition Sensitizes Pancreatic Cancer to Gemcitabine. Co-author DOI 10.3390/life16091560↗
  2. An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms. Co-author DOI 10.1038/s41467-022-33037-x↗
  3. Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic… Co-author DOI 10.1002/cam4.1974↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hong-Juan Yao · 2 shared papers, 2019–2022 · strength 0.23
  2. Rong‐Guang Shao · 2 shared papers, 2019–2022 · strength 0.23
  3. Liang Li · 2 shared papers, 2019–2022 · strength 0.23
  4. Tongshan Zhu · 1 shared paper, 2026 · strength 0.22
  5. Xiaoming Song · 1 shared paper, 2026 · strength 0.22
  6. Yuchen Shi · 1 shared paper, 2022 · strength 0.13
  7. Xiaofei Zhou · 1 shared paper, 2022 · strength 0.13
  8. Hebing Chen · 1 shared paper, 2022 · strength 0.13
  9. Yi Li · 1 shared paper, 2022 · strength 0.13
  10. Li Zhang · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.